ID   TAF1_HUMAN              Reviewed;        1832 AA.
AC   P21675-3;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 2.
DT   12-OCT-2022, entry version 233.
DE   RecName: Full=Isoform 3 of Transcription initiation factor TFIID subunit 1;
DE            EC=2.3.1.48 {ECO:0000269|PubMed:15870300};
DE            EC=2.7.11.1;
DE   AltName: Full=Cell cycle gene 1 protein;
DE   AltName: Full=TBP-associated factor 250 kDa;
DE            Short=p250;
DE   AltName: Full=Transcription initiation factor TFIID 250 kDa subunit;
DE            Short=TAF(II)250;
DE            Short=TAFII-250;
DE            Short=TAFII250;
GN   Name=TAF1; Synonyms=BA2R, CCG1, CCGS, TAF2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Laryngeal carcinoma;
RX   PubMed=2038334; DOI=10.1128/mcb.11.6.3317-3325.1991;
RA   Sekiguchi T., Nohiro Y., Nakamura Y., Hisamoto N., Nishimoto T.;
RT   "The human CCG1 gene, essential for progression of the G1 phase, encodes a
RT   210-kilodalton nuclear DNA-binding protein.";
RL   Mol. Cell. Biol. 11:3317-3325(1991).
RN   [2]
RP   PRELIMINARY NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3169001; DOI=10.1002/j.1460-2075.1988.tb02996.x;
RA   Sekiguchi T., Miyata T., Nishimoto T.;
RT   "Molecular cloning of the cDNA of human X chromosomal gene (CCG1) which
RT   complements the temperature-sensitive G1 mutants, tsBN462 and ts13, of the
RT   BHK cell line.";
RL   EMBO J. 7:1683-1687(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH TBP AND TAFS.
RX   PubMed=7680771; DOI=10.1038/362175a0;
RA   Ruppert S., Wang E.H., Tjian R.;
RT   "Cloning and expression of human TAFII250: a TBP-associated factor
RT   implicated in cell-cycle regulation.";
RL   Nature 362:175-179(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM N-TAF1), AND INVOLVEMENT IN DYT3.
RC   TISSUE=Brain;
RX   PubMed=17273961; DOI=10.1086/512129;
RA   Makino S., Kaji R., Ando S., Tomizawa M., Yasuno K., Goto S., Matsumoto S.,
RA   Tabuena M.D., Maranon E., Dantes M., Lee L.V., Ogasawara K., Tooyama I.,
RA   Akatsu H., Nishimura M., Tamiya G.;
RT   "Reduced neuron-specific expression of the TAF1 gene is associated with X-
RT   linked dystonia-parkinsonism.";
RL   Am. J. Hum. Genet. 80:393-406(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-269.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 837-1872 (ISOFORM 4).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1347-1801 (ISOFORMS 2A; 2C AND 2D),
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1347-1592 (ISOFORM 2E), NUCLEOTIDE SEQUENCE
RP   [MRNA] OF 1498-1801 (ISOFORM 3), AND INVOLVEMENT IN DYT3.
RC   TISSUE=Fetal brain;
RX   PubMed=12928496; DOI=10.1073/pnas.1831949100;
RA   Nolte D., Niemann S., Muller U.;
RT   "Specific sequence changes in multiple transcript system DYT3 are
RT   associated with X-linked dystonia parkinsonism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:10347-10352(2003).
RN   [9]
RP   SEQUENCE REVISION.
RA   Nolte D.;
RL   Submitted (MAY-2007) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1347-1801 (ISOFORMS 2E; 2G; 2H AND 2I), AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=17952504; DOI=10.1007/s00335-007-9063-z;
RA   Herzfeld T., Nolte D., Muller U.;
RT   "Structural and functional analysis of the human TAF1/DYT3 multiple
RT   transcript system.";
RL   Mamm. Genome 18:787-795(2007).
RN   [11]
RP   FUNCTION.
RX   PubMed=8450888; DOI=10.1038/362179a0;
RA   Hisatake K., Hasegawa S., Takada R., Nakatani Y., Horikoshi M.,
RA   Roeder R.G.;
RT   "The p250 subunit of native TATA box-binding factor TFIID is the cell-cycle
RT   regulatory protein CCG1.";
RL   Nature 362:179-181(1993).
RN   [12]
RP   FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-137 AND SER-307, AND
RP   ATP-BINDING.
RX   PubMed=8625415; DOI=10.1016/s0092-8674(00)81055-7;
RA   Dikstein R., Ruppert S., Tjian R.;
RT   "TAFII250 is a bipartite protein kinase that phosphorylates the base
RT   transcription factor RAP74.";
RL   Cell 84:781-790(1996).
RN   [13]
RP   INTERACTION WITH SV40 LARGE T ANTIGEN (MICROBIAL INFECTION).
RX   PubMed=8647434; DOI=10.1101/gad.10.11.1369;
RA   Damania B., Alwine J.C.;
RT   "TAF-like function of SV40 large T antigen.";
RL   Genes Dev. 10:1369-1381(1996).
RN   [14]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS 1 ICP4 (MICROBIAL INFECTION).
RX   PubMed=8649420; DOI=10.1128/mcb.16.6.3085;
RA   Carrozza M.J., DeLuca N.A.;
RT   "Interaction of the viral activator protein ICP4 with TFIID through
RT   TAF250.";
RL   Mol. Cell. Biol. 16:3085-3093(1996).
RN   [15]
RP   FUNCTION, AND MUTAGENESIS.
RX   PubMed=9660973; DOI=10.1016/s1097-2765(00)80089-1;
RA   O'Brien T., Tjian R.;
RT   "Functional analysis of the human TAFII250 N-terminal kinase domain.";
RL   Mol. Cell 1:905-911(1998).
RN   [16]
RP   FUNCTION, ACTIVITY REGULATION, INTERACTION WITH RB1, AND ATP-BINDING.
RX   PubMed=9858607; DOI=10.1128/mcb.19.1.846;
RA   Siegert J.L., Robbins P.D.;
RT   "Rb inhibits the intrinsic kinase activity of TATA-binding protein-
RT   associated factor TAFII250.";
RL   Mol. Cell. Biol. 19:846-854(1999).
RN   [17]
RP   INTERACTION WITH ASF1A.
RX   PubMed=10759893; DOI=10.1046/j.1365-2443.2000.00319.x;
RA   Munakata T., Adachi N., Yokoyama N., Kuzuhara T., Horikoshi M.;
RT   "A human homologue of yeast anti-silencing factor has histone chaperone
RT   activity.";
RL   Genes Cells 5:221-233(2000).
RN   [18]
RP   FUNCTION.
RX   PubMed=11278496; DOI=10.1074/jbc.m009385200;
RA   Solow S., Salunek M., Ryan R., Lieberman P.M.;
RT   "Taf(II) 250 phosphorylates human transcription factor IIA on serine
RT   residues important for TBP binding and transcription activity.";
RL   J. Biol. Chem. 276:15886-15892(2001).
RN   [19]
RP   ACTIVITY REGULATION, AND INTERACTION WITH TAF7.
RX   PubMed=11592977; DOI=10.1073/pnas.211444798;
RA   Gegonne A., Weissman J.D., Singer D.S.;
RT   "TAFII55 binding to TAFII250 inhibits its acetyltransferase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:12432-12437(2001).
RN   [20]
RP   INTERACTION WITH ASF1A.
RX   PubMed=12093919; DOI=10.1073/pnas.142627899;
RA   Chimura T., Kuzuhara T., Horikoshi M.;
RT   "Identification and characterization of CIA/ASF1 as an interactor of
RT   bromodomains associated with TFIID.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:9334-9339(2002).
RN   [21]
RP   INTERACTION WITH ASF1A AND ASF1B.
RX   PubMed=12842904; DOI=10.1074/jbc.m303549200;
RA   Umehara T., Horikoshi M.;
RT   "Transcription initiation factor IID-interactive histone chaperone CIA-II
RT   implicated in mammalian spermatogenesis.";
RL   J. Biol. Chem. 278:35660-35667(2003).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH TP53.
RX   PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6;
RA   Li H.-H., Li A.G., Sheppard H.M., Liu X.;
RT   "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for
RT   TAF1 in cell G1 progression.";
RL   Mol. Cell 13:867-878(2004).
RN   [23]
RP   IDENTIFICATION IN THE MLL1/MLL COMPLEX.
RX   PubMed=15960975; DOI=10.1016/j.cell.2005.04.031;
RA   Dou Y., Milne T.A., Tackett A.J., Smith E.R., Fukuda A., Wysocka J.,
RA   Allis C.D., Chait B.T., Hess J.L., Roeder R.G.;
RT   "Physical association and coordinate function of the H3 K4
RT   methyltransferase MLL1 and the H4 K16 acetyltransferase MOF.";
RL   Cell 121:873-885(2005).
RN   [24]
RP   HISTONE ACETYLTRANSFERASE ACTIVITY, AND MUTAGENESIS OF GLU-721 AND
RP   827-MET--ASP-829.
RX   PubMed=15870300; DOI=10.1128/mcb.25.10.4321-4332.2005;
RA   Hilton T.L., Li Y., Dunphy E.L., Wang E.H.;
RT   "TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1
RT   promoter.";
RL   Mol. Cell. Biol. 25:4321-4332(2005).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1826, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1700 (ISOFORMS 2A AND 4),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1702 (ISOFORM 2G),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1697 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   ACTIVITY REGULATION.
RX   PubMed=22711989; DOI=10.1128/mcb.00416-12;
RA   Kloet S.L., Whiting J.L., Gafken P., Ranish J., Wang E.H.;
RT   "Phosphorylation-dependent regulation of cyclin D1 and cyclin A gene
RT   transcription by TFIID subunits TAF1 and TAF7.";
RL   Mol. Cell. Biol. 32:3358-3369(2012).
RN   [29]
RP   MISCELLANEOUS.
RX   PubMed=23184149; DOI=10.1093/hmg/dds499;
RA   Herzfeld T., Nolte D., Grznarova M., Hofmann A., Schultze J.L., Muller U.;
RT   "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific
RT   sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and
RT   dopamine metabolism.";
RL   Hum. Mol. Genet. 22:941-951(2013).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-549 AND LYS-562, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1359-1638.
RX   PubMed=10827952; DOI=10.1126/science.288.5470.1422;
RA   Jacobson R.H., Ladurner A.G., King D.S., Tjian R.;
RT   "Structure and function of a human TAFII250 double bromodomain module.";
RL   Science 288:1422-1425(2000).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) OF 1501-1635, AND SUBUNIT.
RX   PubMed=22464331; DOI=10.1016/j.cell.2012.02.013;
RA   Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P.,
RA   Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T.,
RA   Gingras A.C., Arrowsmith C.H., Knapp S.;
RT   "Histone recognition and large-scale structural analysis of the human
RT   bromodomain family.";
RL   Cell 149:214-231(2012).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 579-1215 IN COMPLEX WITH TAF7,
RP   FUNCTION, AND INTERACTION WITH TAF7.
RX   PubMed=25412659; DOI=10.1038/cr.2014.148;
RA   Wang H., Curran E.C., Hinds T.R., Wang E.H., Zheng N.;
RT   "Crystal structure of a TAF1-TAF7 complex in human transcription factor IID
RT   reveals a promoter binding module.";
RL   Cell Res. 24:1433-1444(2014).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 1497-1638 IN COMPLEX WITH
RP   CROTONYLATED OR BUTYRYLATED HISTONE H4.
RX   PubMed=26365797; DOI=10.1016/j.str.2015.08.004;
RA   Flynn E.M., Huang O.W., Poy F., Oppikofer M., Bellon S.F., Tang Y.,
RA   Cochran A.G.;
RT   "A subset of human bromodomains recognizes butyryllysine and crotonyllysine
RT   histone peptide modifications.";
RL   Structure 23:1801-1814(2015).
RN   [36]
RP   STRUCTURE BY ELECTRON MICROSCOPY (8.50 ANGSTROMS), AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=27007846; DOI=10.1038/nature17394;
RA   Louder R.K., He Y., Lopez-Blanco J.R., Fang J., Chacon P., Nogales E.;
RT   "Structure of promoter-bound TFIID and model of human pre-initiation
RT   complex assembly.";
RL   Nature 531:604-609(2016).
RN   [37] {ECO:0007744|PDB:6FIC}
RP   X-RAY CRYSTALLOGRAPHY (2.18 ANGSTROMS) OF 1359-1638.
RA   Mathea S., Suh J.L., Salah E., Tallant C., Siejka P., Pike A.C.W.,
RA   von Delft F., Arrowsmith C.H., Edwards A.M., Bountra C., James L.I.,
RA   Frye S.V., Knapp S.;
RT   "Bivalent Inhibitor UNC4512 Bound to the TAF1 Bromodomain Tandem.";
RL   Submitted (JAN-2018) to the PDB data bank.
RN   [38] {ECO:0007744|PDB:6P39, ECO:0007744|PDB:6P3A}
RP   X-RAY CRYSTALLOGRAPHY (2.94 ANGSTROMS) OF 1500-1635.
RA   Seo H.-S., Dhe-Paganon S.;
RT   "Crystal Structure Analysis of TAF1 Bromodomain.";
RL   Submitted (MAY-2019) to the PDB data bank.
RN   [39] {ECO:0007744|PDB:7JJG}
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to
RT   ATR kinase inhibitor AZ20.";
RL   Submitted (JUL-2020) to the PDB data bank.
RN   [40] {ECO:0007744|PDB:7JJH}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the unliganded tandem bromodomain (BD1, BD2) of human
RT   TAF1.";
RL   Submitted (JUL-2020) to the PDB data bank.
RN   [41] {ECO:0007744|PDB:7JSP}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to
RT   the ATR kinase inhibitor AZD6738.";
RL   Submitted (AUG-2020) to the PDB data bank.
RN   [42] {ECO:0007744|PDB:7JTC}
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to
RT   ZS1-322.";
RL   Submitted (AUG-2020) to the PDB data bank.
RN   [43] {ECO:0007744|PDB:7K03}
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1
RT   bound to ATR kinase inhibitor AZD6738.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [44] {ECO:0007744|PDB:7K0D}
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound
RT   to mTORC1/2 inhibitor AZD3147.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [45] {ECO:0007744|PDB:7K0U}
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to
RT   PLK1 kinase inhibitor BI2536.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [46] {ECO:0007744|PDB:7K1P}
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to
RT   bromosporine.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [47] {ECO:0007744|PDB:7K27}
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound
RT   to ATR inhibitor AZ20.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [48] {ECO:0007744|PDB:7K3O}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the unliganded second bromodomain (BD2) of human
RT   TAF1.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [49] {ECO:0007744|PDB:7K42}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to
RT   dioxane.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [50] {ECO:0007744|PDB:7K6F}
RP   X-RAY CRYSTALLOGRAPHY (1.86 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Bikowitz M.J., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 in
RT   complex with MES (2-(N-morpholino)ethanesulfonic acid).";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [51] {ECO:0007744|PDB:7L6X}
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound
RT   to GNE-371.";
RL   Submitted (DEC-2020) to the PDB data bank.
RN   [52] {ECO:0007744|PDB:7LB0}
RP   X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound
RT   to ZS1-295.";
RL   Submitted (JAN-2021) to the PDB data bank.
RN   [53] {ECO:0007744|PDB:7LB1}
RP   X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound
RT   to ZS1-585.";
RL   Submitted (JAN-2021) to the PDB data bank.
RN   [54] {ECO:0007744|PDB:7LB2}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound
RT   to ZS1-589.";
RL   Submitted (JAN-2021) to the PDB data bank.
RN   [55] {ECO:0007744|PDB:7N42}
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain of human TAF1 (TAF1-T) bound
RT   to ZS1-681.";
RL   Submitted (JUN-2021) to the PDB data bank.
RN   [56] {ECO:0007744|PDB:7EDX, ECO:0007744|PDB:7EG7, ECO:0007744|PDB:7EG8, ECO:0007744|PDB:7EG9, ECO:0007744|PDB:7EGA, ECO:0007744|PDB:7EGB, ECO:0007744|PDB:7EGC, ECO:0007744|PDB:7EGD, ECO:0007744|PDB:7EGE, ECO:0007744|PDB:7EGH}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.04 ANGSTROMS), FUNCTION, IDENTIFICATION
RP   IN THE TFIID COMPLEX, AND SUBUNIT.
RX   PubMed=33795473; DOI=10.1126/science.aba8490;
RA   Chen X., Qi Y., Wu Z., Wang X., Li J., Zhao D., Hou H., Li Y., Yu Z.,
RA   Liu W., Wang M., Ren Y., Li Z., Yang H., Xu Y.;
RT   "Structural insights into preinitiation complex assembly on core
RT   promoters.";
RL   Science 372:0-0(2021).
RN   [57]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-269; GLY-297; ASP-453; LYS-651 AND
RP   ILE-691.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [58]
RP   INVOLVEMENT IN MRXS33, AND VARIANTS MRXS33 SER-575; ARG-786; HIS-955;
RP   TRP-1225; THR-1316; HIS-1431 AND HIS-1496.
RX   PubMed=26637982; DOI=10.1016/j.ajhg.2015.11.005;
RA   O'Rawe J.A., Wu Y., Doerfel M.J., Rope A.F., Au P.Y., Parboosingh J.S.,
RA   Moon S., Kousi M., Kosma K., Smith C.S., Tzetis M., Schuette J.L.,
RA   Hufnagel R.B., Prada C.E., Martinez F., Orellana C., Crain J.,
RA   Caro-Llopis A., Oltra S., Monfort S., Jimenez-Barron L.T., Swensen J.,
RA   Ellingwood S., Smith R., Fang H., Ospina S., Stegmann S., Den Hollander N.,
RA   Mittelman D., Highnam G., Robison R., Yang E., Faivre L., Roubertie A.,
RA   Riviere J.B., Monaghan K.G., Wang K., Davis E.E., Katsanis N.,
RA   Kalscheuer V.M., Wang E.H., Metcalfe K., Kleefstra T., Innes A.M.,
RA   Kitsiou-Tzeli S., Rosello M., Keegan C.E., Lyon G.J.;
RT   "TAF1 Variants Are Associated with Dysmorphic Features, Intellectual
RT   Disability, and Neurological Manifestations.";
RL   Am. J. Hum. Genet. 97:922-932(2015).
RN   [59]
RP   VARIANTS ASP-472 AND CYS-1169.
RX   PubMed=25644381; DOI=10.1038/mp.2014.193;
RA   Hu H., Haas S.A., Chelly J., Van Esch H., Raynaud M., de Brouwer A.P.,
RA   Weinert S., Froyen G., Frints S.G., Laumonnier F., Zemojtel T., Love M.I.,
RA   Richard H., Emde A.K., Bienek M., Jensen C., Hambrock M., Fischer U.,
RA   Langnick C., Feldkamp M., Wissink-Lindhout W., Lebrun N., Castelnau L.,
RA   Rucci J., Montjean R., Dorseuil O., Billuart P., Stuhlmann T., Shaw M.,
RA   Corbett M.A., Gardner A., Willis-Owen S., Tan C., Friend K.L., Belet S.,
RA   van Roozendaal K.E., Jimenez-Pocquet M., Moizard M.P., Ronce N., Sun R.,
RA   O'Keeffe S., Chenna R., van Boemmel A., Goeke J., Hackett A., Field M.,
RA   Christie L., Boyle J., Haan E., Nelson J., Turner G., Baynam G.,
RA   Gillessen-Kaesbach G., Mueller U., Steinberger D., Budny B.,
RA   Badura-Stronka M., Latos-Bielenska A., Ousager L.B., Wieacker P.,
RA   Rodriguez Criado G., Bondeson M.L., Anneren G., Dufke A., Cohen M.,
RA   Van Maldergem L., Vincent-Delorme C., Echenne B., Simon-Bouy B.,
RA   Kleefstra T., Willemsen M., Fryns J.P., Devriendt K., Ullmann R.,
RA   Vingron M., Wrogemann K., Wienker T.F., Tzschach A., van Bokhoven H.,
RA   Gecz J., Jentsch T.J., Chen W., Ropers H.H., Kalscheuer V.M.;
RT   "X-exome sequencing of 405 unresolved families identifies seven novel
RT   intellectual disability genes.";
RL   Mol. Psychiatry 21:133-148(2016).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=12;
CC         Comment=the TAF1/DYT3 multiple transcript system is composed of 38
CC         evolutionary conserved exons plus 5 downstream exons referred to as
CC         exons d1-d5 that are primate-specific. Multiple highly polymorphic
CC         variants can be generated by splicing exons d3 and d4 to various
CC         combinations of exons 1-37.;
CC       Name=1;
CC         IsoId=P21675-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P21675-2; Sequence=VSP_012362;
CC       Name=3;
CC         IsoId=P21675-3; Sequence=VSP_053382, VSP_053383, VSP_053384;
CC       Name=4;
CC         IsoId=P21675-4; Sequence=VSP_053383;
CC       Name=2a;
CC         IsoId=P21675-5; Sequence=VSP_053383, VSP_053384;
CC       Name=2c;
CC         IsoId=P21675-6; Sequence=VSP_053384;
CC       Name=2d;
CC         IsoId=P21675-7; Sequence=VSP_053381, VSP_053384;
CC       Name=2e; Synonyms=2F;
CC         IsoId=P21675-8; Sequence=VSP_053379, VSP_053380;
CC       Name=2g;
CC         IsoId=P21675-9; Sequence=VSP_053381, VSP_053383, VSP_053384;
CC       Name=2h;
CC         IsoId=P21675-10; Sequence=VSP_053375, VSP_053377;
CC       Name=2i;
CC         IsoId=P21675-11; Sequence=VSP_053376, VSP_053378;
CC       Name=N-TAF1; Synonyms=TA14-391;
CC         IsoId=P21675-12; Sequence=VSP_012362, VSP_053381;
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   ProteomicsDB; 53888; -.
DR   Proteomes; UP000005640; Chromosome X.
PE   1: Evidence at protein level;
FT   MOD_RES         1697
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
SQ   SEQUENCE   1832 AA;  208364 MW;  6C51A0F5885FF667 CRC64;
     MGPGCDLLLR TAATITAAAI MSDTDSDEDS AGGGPFSLAG FLFGNINGAG QLEGESVLDD
     ECKKHLAGLG ALGLGSLITE LTANEELTGT DGALVNDEGW VRSTEDAVDY SDINEVAEDE
     SRRYQQTMGS LQPLCHSDYD EDDYDADCED IDCKLMPPPP PPPGPMKKDK DQDSITGEKV
     DFSSSSDSES EMGPQEATQA ESEDGKLTLP LAGIMQHDAT KLLPSVTELF PEFRPGKVLR
     FLRLFGPGKN VPSVWRSARR KRKKKHRELI QEEQIQEVEC SVESEVSQKS LWNYDYAPPP
     PPEQCLSDDE ITMMAPVESK FSQSTGDIDK VTDTKPRVAE WRYGPARLWY DMLGVPEDGS
     GFDYGFKLRK TEHEPVIKSR MIEEFRKLEE NNGTDLLADE NFLMVTQLHW EDDIIWDGED
     VKHKGTKPQR ASLAGWLPSS MTRNAMAYNV QQGFAATLDD DKPWYSIFPI DNEDLVYGRW
     EDNIIWDAQA MPRLLEPPVL TLDPNDENLI LEIPDEKEEA TSNSPSKESK KESSLKKSRI
     LLGKTGVIKE EPQQNMSQPE VKDPWNLSND EYYYPKQQGL RGTFGGNIIQ HSIPAVELRQ
     PFFPTHMGPI KLRQFHRPPL KKYSFGALSQ PGPHSVQPLL KHIKKKAKMR EQERQASGGG
     EMFFMRTPQD LTGKDGDLIL AEYSEENGPL MMQVGMATKI KNYYKRKPGK DPGAPDCKYG
     ETVYCHTSPF LGSLHPGQLL QAFENNLFRA PIYLHKMPET DFLIIRTRQG YYIRELVDIF
     VVGQQCPLFE VPGPNSKRAN THIRDFLQVF IYRLFWKSKD RPRRIRMEDI KKAFPSHSES
     SIRKRLKLCA DFKRTGMDSN WWVLKSDFRL PTEEEIRAMV SPEQCCAYYS MIAAEQRLKD
     AGYGEKSFFA PEEENEEDFQ MKIDDEVRTA PWNTTRAFIA AMKGKCLLEV TGVADPTGCG
     EGFSYVKIPN KPTQQKDDKE PQPVKKTVTG TDADLRRLSL KNAKQLLRKF GVPEEEIKKL
     SRWEVIDVVR TMSTEQARSG EGPMSKFARG SRFSVAEHQE RYKEECQRIF DLQNKVLSST
     EVLSTDTDSS SAEDSDFEEM GKNIENMLQN KKTSSQLSRE REEQERKELQ RMLLAAGSAA
     SGNNHRDDDT ASVTSLNSSA TGRCLKIYRT FRDEEGKEYV RCETVRKPAV IDAYVRIRTT
     KDEEFIRKFA LFDEQHREEM RKERRRIQEQ LRRLKRNQEK EKLKGPPEKK PKKMKERPDL
     KLKCGACGAI GHMRTNKFCP LYYQTNAPPS NPVAMTEEQE EELEKTVIHN DNEELIKVEG
     TKIVLGKQLI ESADEVRRKS LVLKFPKQQL PPKKKRRVGT TVHCDYLNRP HKSIHRRRTD
     PMVTLSSILE SIINDMRDLP NTYPFHTPVN AKVVKDYYKI ITRPMDLQTL RENVRKRLYP
     SREEFREHLE LIVKNSATYN GPKHSLTQIS QSMLDLCDEK LKEKEDKLAR LEKAINPLLD
     DDDQVAFSFI LDNIVTQKMM AVPDSWPFHH PVNKKFVPDY YKVIVNPMDL ETIRKNISKH
     KYQSRESFLD DVNLILANSV KYNGPESQYT KTAQEIVNVC YQTLTEYDEH LTQLEKDICT
     AKEAALEEAE LESLDPMTPG PYTPQPPDLY DTNTSLSMSR DASVFQDESN MSVLDIPSAT
     PEKQMRQGRG RLGEEDSDVD IEGYDDEEED GKPKTPAPEG EDGDGDLADE EEGTVQQPQA
     SVLYEDLLMS EGEDDEEDAG SDEEGDNPFS AIQLSESGSD SDVGSGGIRP KQPRMLQENT
     RMDMENEESM MSYEGDGGEA SHGLEDSNIR YQ
//
